Christopher Maisel
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
-
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
- Hematology 20
- Multiple Myeloma Research and Treatments 17
- Acute Myeloid Leukemia Research 4
- Chronic Myeloid Leukemia Treatments 3
- Oncology 10
- Peptidase Inhibition and Analysis 5
- Cancer Treatment and Pharmacology 4
- Co-authors
- Nizar J. Bahlis (7 shared papers)Scot C. Remick (1 shared paper)Stanton L. Gerson (1 shared paper)Joseph W. Fay (3 shared papers)Pingfu Fu (1 shared paper)Edward Agura (2 shared papers)Xavier Leleu (11 shared papers)R.B. Berryman (3 shared papers)
- Journals
- Blood (5 papers)Journal of Clinical Oncology (5 papers)HemaSphere (3 papers)British Journal of Haematology (1 paper)The Oncologist (1 paper)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Christopher Maisel
20 papers receiving 138 citations
Peers
Comparison fields: 5 of 25
- Hematology 86
- Oncology 49
- Genetics 13
- Molecular Biology 69
- Cancer Research 9
Countries citing papers authored by Christopher Maisel
This map shows the geographic impact of Christopher Maisel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Maisel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Maisel more than expected).
Fields of papers citing papers by Christopher Maisel
This network shows the impact of papers produced by Christopher Maisel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Maisel. The network helps show where Christopher Maisel may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Maisel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 26 | |
| 2 | 2007 | 25 | |
| 3 | 2011 | 24 | |
| 4 | 2018 | 11 | |
| 5 | 2019 | 10 | |
| 6 | 2006 | 9 | |
| 7 | 2021 | 9 | |
| 8 | 2020 | 5 | |
| 9 | 2023 | 3 | |
| 10 | 2023 | 3 | |
| 11 | 2023 | 2 | |
| 12 | 2007 | 2 | |
| 13 | 2019 | 2 | |
| 14 | 2019 | 2 | |
| 15 | 2023 | 1 | |
| 16 | 2019 | 1 | |
| 17 | 2021 | 1 | |
| 18 | 2014 | 1 | |
| 19 | 2019 | 1 | |
| 20 | 2023 | 1 |
About Christopher Maisel
Christopher Maisel is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Infectious Diseases, having authored 20 papers that have together received 139 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (6 papers), Peptidase Inhibition and Analysis (5 papers), Acute Myeloid Leukemia Research (4 papers), Cancer Treatment and Pharmacology (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Histone Deacetylase Inhibitors Research (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). The work is most often cited by research in Hematology (86 citations), Oncology (49 citations), Genetics (13 citations), Molecular Biology (69 citations) and Cancer Research (9 citations). Christopher Maisel has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Nizar J. Bahlis, Scot C. Remick, Stanton L. Gerson, Joseph W. Fay, Pingfu Fu, Edward Agura, Xavier Leleu, R.B. Berryman, Houston Holmes and Giovanna Saracino. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, British Journal of Haematology and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.